EphemerisX Research · Deep research
Cross-investigations whose records belong together as a shared concern. How this research works →
AllComparable evidenceDivergent outcomeRegulatory pathwayShared concern
CorMedix's DefenCath and Verrica's VP-102 each received FDA letters that, by the companies' accounts, turned on a third party's facility. One was approved with the same manufacturer; the other moved its bulk solution elsewhere.
Verrica, CorMedix and Replimune each told investors that an FDA letter raised no efficacy or safety issue, or no safety issue. Set beside the letters' searchable text, each statement covers some of the letter's subjects and not others.
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →
